Biotech Values

[urche]

ASPV:

"It's a compelling value, but I believe the analysts and larger institutions are playing the wait to see game about whether or not mgmt can competently in-license another product to help off-set the upcoming revenue hit from the patent expiration."

If true that would put a damper on stock movement because institutional holdings are huge --- like 75%--- and insider control is listed at 25%.